Twitter | Search | |
Search Refresh
Alpharmaxim Oct 17
New released this week is another piece of good news for . When treated with Genentech’s Rituxan (rituximab), 40% of patients with vulgaris (a rare, condition) achieved sustained complete remission. Read more:
Reply Retweet Like
Cory Simpson 21h
Kudos to Dr. Joly and co-authors for another landmark study for patients with , one of the many serious diseases treated by . Hoping this evidence will help patients get access to
Reply Retweet Like
Genentech Oct 14
ICYMI: Data from a Phase III study reinforced the safety and efficacy of our medicine for adults with vulgaris. Learn more:
Reply Retweet Like
Thomais Sogia Oct 12
In paraneoplastic pemphigus we may have organ involvement ( bronchiolitis, involvement of the intestinal or urinary tract) because Envoplakin and Periplakin are the main target antigens
Reply Retweet Like
Lisa Weinberger Oct 15
We need more research and approved treatments. My just got FDA approved treatment last June, the same month I was diagnosed. Without I doubt would have gotten this approval & many of us wouldn't be alive.
Reply Retweet Like
Cory Simpson Oct 12
Excited to be at the International Pemphigus and Pemphigoid Foundation () conference for patient education with other providers from It’s amazing how sharing real patient stories about can make an impact
Reply Retweet Like
Genentech Oct 13
: Data from our Phase III study shows effectiveness of our medicine in people with vulgaris. Learn more:
Reply Retweet Like
Roche Oct 14
We are excited to have presented late-breaking Phase III data at from our study for vulgaris - a rare and potentially life-threatening autoimmune condition. Read more here
Reply Retweet Like
DDNews Online Oct 10
upbeat on early Ph2 data for vs To date, report 40% CR w/ oral inhibitor & 60% of 1 or 0. Currently recruiting for Ph3 study
Reply Retweet Like
Stephanie Fischer Oct 13
Glad to be at Patient Education Conference in Philadelphia. IPPF offers a range of resources for & patients & caregivers from Patient Education Webinars to Peer Health Coaches to support groups. Learn more at .
Reply Retweet Like
Roche Oct 14
Our late-breaking Phase III data, presented at , provides additional evidence towards the effectiveness of our for vulgaris, a rare condition affecting 3 in every 100,000 people. Read more here
Reply Retweet Like
NatureRevDisPrimers Oct 12
Learn more about the current and future therapeutic strategies for with our Primer
Reply Retweet Like
BioTek reMEDys Oct 11
So excited to be at the International Pemphigus Pemphigoid Foundation’s patient education conference! Come visit us!! @ Wyndham Philadelphia Historic…
Reply Retweet Like
Thomais Sogia Oct 12
The main targets in paraneoplastic pemphigus are Envoplakin and Periplakin vs Pemphigus vulgaris with main targets Desmoglein 3 and Desmoglein 1
Reply Retweet Like
TrialSite News Oct 13
Reply Retweet Like
Thomais Sogia Oct 12
Prof. Katarzyna Wozniak described the diagnostic criteria of paraneoplastic pemphigus
Reply Retweet Like